In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH ✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis ✳️TRAF5 overexpression attenuated PAH sxs in mice TRAF5 as potential BM for dx/novel tx target in SLE-PAH? #ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s

Important plenary re:reduced vs standard GC for AAV... IRL PEXIVAS & recent guidelines supported low dose taper Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts Need full data but yikes... @RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok

Abst#0725 #ACR23 @RheumNow PEXIVAS Real life data! GPA & MPA pts - Retrosp observ study ⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx ⚠️Caution w/ reduced GC, RTX, severe kidney dis #ACRBest https://t.co/7qI5c1ZiqO

Look who I interviewed for @RheumNow!!@ashira_md shares the story of APOL1 effects on SLE . Patients with the variants have more aggressive renal and vascular disease. #DuboisLecture #ACR23 #StrongWomen #FutureNobelRecipient https://t.co/IzRsHwaMIb

Interesting study on PEXIVAS reduced steroid use from today's plenary session! Reduced steroid dose in GPA/MPA pts associated w/ INCREASED risk of death, ESKD, progression of dz Even greater risk in pts with higher Cr lvls or RTX induction use @RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf

In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs Further prospective studies req'd? BEL remains an option for non-renal SLE tx. #ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk

Did you know? 👉APOL1 variants are protective against trypanosomiasis. 👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had: ⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ

Abs#0726 #ACR23 @RheumNow MSUS recs in Canadian Rheum training 🇨🇦: Focus MSUS exam of hands/wrists/feet: ID effusion, synov, erosions v osteophyte, tenosyn Limited MSUS of knee/ankle for effusion @USSONAR_Rh @MymaAlbaydaMD Agree: MSUS should be part of rheum training for all https://t.co/UNPpAA1p0V

Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those with severe GPA/MPA HR 1.72. More marked in those with creat>300 or with RTX induction Abstr#0725 #ACR23 @RheumNow https://t.co/vTXVZfjbXx https://t.co/4FuMjxOuyB

Should there be a minimum ultrasound training as competencies in rheumatology training? Abst0726 #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ #RheumEd #POCUS https://t.co/mqdcPEeMYW

INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials like this against placebo? Surely a non-inferiority vs s/c secukinumab is more ethical. Abstr#0776 #ACR23 @RheumNow https://t.co/Usw0iwZEF5 https://t.co/DP6Gb4pF8a